Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499
Sign Up to like & getrecommendations! Published in 2017 at "Leukemia"
DOI: 10.1038/leu.2016.305
Abstract: Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90 Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499 read more here.
Keywords: initial therapy; abbreviated chop; mantle cell; therapy abbreviated ... See more keywords
Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13649
Abstract: While most patients with mantle cell lymphoma (MCL) receive therapy shortly after diagnosis, a subset of patients with indolent‐behaving disease can safely defer treatment. In this subgroup, we evaluated the importance of treatment intensity in… read more here.
Keywords: intensive induction; mantle cell; initial therapy; cell lymphoma ... See more keywords
Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-7152
Abstract: Background: Peripheral T-cell lymphomas (PTCLs) are a rare subtype of aggressive lymphomas. Cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) has been the standard initial therapy for PTCL; however, clinical outcomes remain suboptimal. The introduction of brentuximab… read more here.
Keywords: relapse; months months; therapy; response ... See more keywords
MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.
Sign Up to like & getrecommendations! Published in 2025 at "Blood advances"
DOI: 10.1182/bloodadvances.2025017760
Abstract: This phase 2 study evaluated the efficacy and safety of combining acalabrutinib (A) and lenalidomide (L) with either rituximab (ALR) or obinutuzumab (ALO), with longitudinal minimal residual disease (MRD) monitoring in frontline MCL treatment (ClinicalTrials.gov… read more here.
Keywords: acalabrutinib lenalidomide; alr; initial therapy; rituximab alr ... See more keywords
Compositional alterations of gut microbiota in children with primary nephrotic syndrome after initial therapy
Sign Up to like & getrecommendations! Published in 2019 at "BMC Nephrology"
DOI: 10.1186/s12882-019-1615-4
Abstract: BackgroundPrimary nephrotic syndrome (PNS) is a common glomerular disease in children. T cell dysfunction plays a crucial role in the pathogenesis of PNS. Moreover, dysbiosis of gut microbiota contributes to immunological disorders. Whether the initial… read more here.
Keywords: therapy; gut microbiota; initial therapy; pns ... See more keywords
Differential response to carfilzomib based on initial therapy with bortezomib in multiple myeloma.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e19515
Abstract: e19515Background: Proteasome inhibitors (PIs) are efficacious in multiple myeloma (MM). In randomized phase 3 studies Carfilzomib doubled the progression free survival (PFS) compared to Bortezomib ... read more here.
Keywords: initial therapy; response carfilzomib; differential response; multiple myeloma ... See more keywords